Article
type: Class

Document
type: Class

Information Content Entity
type: Class

Academic Article
type: Class

http://irises.unisr.it/resource/item/8055
type: Generically Dependent Continuant
related by: 195709
type: Continuant
type: Academic Article
type: Document
type: Thing
type: Information Content Entity
type: Entity
type: Article
most specific type: Academic Article
label: Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial.

Continuant
type: Class

Entity
type: Class

individual
rights: termsOfUse
date: 2026-08-24T02:40:28
publisher: http://irises.unisr.it/resource/item/8055
type: Document
label: RDF description of Patients with aaIPI 2-3 diffuse large B-cell lymphoma achieve 75% long-term survival following first-line rituximab-supplemented high-dose sequential chemotherapy and autograft: Final results of the prospective phase II GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) trial. - http://irises.unisr.it/resource/item/8055

195709
type: Entity
type: BFO_0000020
type: Authorship
type: Relationship
type: Continuant
type: Thing
relates: http://irises.unisr.it/resource/item/8055

Generically Dependent Continuant
type: Class